speb/financial-data huggingface dataset:
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Long Term Capital Lease Obligation: 258420000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 258420000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Long Term Provisions: 114110000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 1139780000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 6506920000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Assets: 85300000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Non Current Prepaid Assets: 176150000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 15519739.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 465120000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 149330000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 6550550000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Other Intangible Assets: 179830000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 120490000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 1139780000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Other Receivables: 490840000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 660540000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Payables: 803980000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 15519739.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 6705750000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 6506920000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 8755360000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 6705750000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Total Debt: 328570000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 6705750000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 2049610000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 1800430000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 590030000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Total Tax Payable: 85230000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: 5495350000.00
EXPLEOSOL.NS income_statement (quarterly, 2024-12-31) — Minority Interests: 0.00
EXPLEOSOL.NS income_statement (quarterly, 2024-12-31) — Other Operating Expenses: 679370000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — +Operating Expense: 2812010000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 612510000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — +Total Revenue: 10247960000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 2557960000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 610810000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 610810000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 2223040000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 2223040000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Accumulated Depreciation: -1024010000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -1024010000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Additional Paid In Capital: 11300000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 11300000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -60680000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -60680000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Amortization: 123750000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Amortization Cash Flow: 123750000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Available For Sale Securities: 62890000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 62890000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 15520595.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 15522888.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Basic EPS: 66.52
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Basic EPS: 15.51
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 1761380000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Buildings And Improvements: 1253560000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 1253560000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Capital Expenditure: -79200000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Capital Lease Obligations: 297980000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 297980000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 155200000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 155200000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 2174860000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 2174860000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 2174860000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 2174860000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Cash Dividends Paid: -775990000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Cash Equivalents: 644080000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Cash Equivalents: 644080000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Cash Financial: 1530780000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Cash Financial: 1530780000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Change In Other Current Assets: -157350000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Change In Other Current Liabilities: -96080000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Change In Payable: 332360000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Change In Receivables: 182100000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: 348160000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Changes In Cash: 391640000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Common Stock: 155200000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 155200000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 6358440000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 6358440000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Construction In Progress: 0.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 0.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 6153370000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 1625940000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Current Assets: 5631600000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 5631600000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Current Capital Lease Obligation: 76540000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 76540000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 76540000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 76540000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Current Deferred Taxes Liabilities: 102850000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Current Deferred Taxes Liabilities: 102850000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 1444570000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 1444570000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 136020000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 136020000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Depreciation: 393070000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 393070000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 393070000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 80530000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 393070000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 80530000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 15520595.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 15522888.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Diluted EPS: 66.52
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: 15.51
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 1032430000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 240760000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Dividends Payable: 470000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Dividends Payable: 470000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — EBIT: 1425620000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — EBIT: 364630000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — EBITDA: 1818690000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — EBITDA: 445160000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Effect Of Exchange Rate Changes: 21840000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — End Cash Position: 2174860000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: -870970000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: 1715010000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Gain Loss On Investment Securities: -26700000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Gain Loss On Sale Of PPE: -270000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — General And Administrative Expense: 1380900000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Goodwill: 0.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Goodwill: 0.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 117790000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 117790000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Gross Accounts Receivable: 2283720000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 2283720000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 2031940000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 2031940000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Gross Profit: 4094590000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 932020000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Hedging Assets Current: 3920000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Hedging Assets Current: 3920000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Interest Expense: 33220000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 9400000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 33220000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 9400000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Interest Income: 82810000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 82810000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -33040000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Interest Received Cfi: 93550000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 6358440000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 6358440000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: -531600000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 62890000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 62890000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Long Term Capital Lease Obligation: 221440000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 221440000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 221440000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 221440000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Long Term Debt Payments: 0.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 126540000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 126540000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 778380000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 778380000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Minority Interest: 0.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Minority Interest: 0.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Minority Interests: 0.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Minority Interests: 0.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: 43380000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Net Income: 1032430000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Net Income: 240760000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 1032430000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 240760000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 1032430000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 240760000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 1032430000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 240760000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 1032430000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 240760000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: 1392400000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: 1032430000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 240760000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Net Interest Income: -33220000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: -9400000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: 132520000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Net Issuance Payments Of Debt: 0.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Net Long Term Debt Issuance: 0.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: -33220000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -9400000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Net PPE: 1007930000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 1007930000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: -78490000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 6240650000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 6240650000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Assets: 129070000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 129070000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 286330000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 286330000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Non Current Prepaid Assets: 237510000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 237510000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: 1818690000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 445160000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Normalized Income: 1065518027.87
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Normalized Income: 240760000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: 1794210000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Operating Income: 1282580000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Operating Income: 319510000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Operating Revenue: 10247960000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 2557960000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 15519739.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 15519739.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: 463260000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 463260000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 228430000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 228430000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Other Equity Interest: 6203240000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 6203240000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Other Intangible Assets: 117790000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 117790000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: -49590000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Other Non Current Assets: 35740000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 35740000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Other Non Operating Income Expenses: 162040000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 45120000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 2418940000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 531980000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Other Payable: 385250000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 385250000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Other Properties: 1007920000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 1007920000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Other Receivables: 620140000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Other Receivables: 620140000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 770440000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 770440000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Other Special Charges: -270000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Payables: 996530000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Payables: 996530000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 205880000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 205880000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 485870000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 485870000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Pretax Income: 1392400000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 355230000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Properties: 0.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Provisionand Write Offof Assets: 82120000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Purchase Of Investment: -6223610000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: -79200000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 6153370000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 1625940000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 393070000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 80530000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Rent And Landing Fees: 26840000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Rent Expense Supplemental: 26840000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Repayment Of Debt: 0.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 123770000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 123770000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Retained Earnings: 7146330000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 7146330000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Sale Of Investment: 6356130000.00
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Sale Of PPE: 710000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 58350000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 1439250000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Share Issued: 15519739.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 15519739.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Special Income Charges: -19000000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Special Income Charges: 0.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 6358440000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 6358440000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 6240650000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 6240650000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: -4911972.13
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Tax Provision: 359970000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Tax Provision: 114470000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.26
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.32
EXPLEOSOL.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -407360000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Total Assets: 8310780000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 8310780000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 6358440000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 6358440000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Total Debt: 297980000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 297980000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 6358440000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 6358440000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Total Expenses: 8965380000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 2238450000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 1952340000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 1952340000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 2679180000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 2679180000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 507770000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 507770000.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Total Tax Payable: 102850000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 102850000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Total Unusual Items: 0.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items: 0.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: -19000000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 0.00
EXPLEOSOL.NS balance_sheet (annual, 2025-03-31) — Working Capital: 4187030000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 4187030000.00
EXPLEOSOL.NS income_statement (annual, 2025-03-31) — Write Off: 0.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 712440000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 2596470000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 15520517.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Basic EPS: 13.16
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 1663510000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 76720000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 76720000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 15520517.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: 13.16
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 204250000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — EBIT: 289970000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — EBITDA: 366690000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 932960000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 6410000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 6410000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Net Income: 204250000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 204250000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 204250000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 204250000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 204250000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 204250000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -6410000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -6410000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 366690000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Normalized Income: 204250000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Operating Income: 220520000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 2596470000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 69450000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 635720000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Pretax Income: 283560000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 1663510000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 76720000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Special Income Charges: 0.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 79310000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.28
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 2375950000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items: 0.00
EXPLEOSOL.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 0.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — +Operating Expense: 74360000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — +Total Revenue: 2826950000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 828450000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 2488750000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Available For Sale Securities: 57200000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Basic Average Shares: 15518735.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Basic EPS: 25.62
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 201640000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Capital Stock: 155200000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 2819550000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 3664780000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Common Stock: 155200000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 7036500000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 1777480000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Current Assets: 6546580000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 68900000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 68900000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 1801320000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Current Provisions: 156830000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 74360000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Depreciation Income Statement: 74360000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 15518735.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Diluted EPS: 25.62
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 397590000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — EBIT: 519790000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — EBITDA: 594150000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 57340000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Gross PPE: 854750000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Gross Profit: 1049470000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Interest Expense: 5990000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 5990000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Invested Capital: 7036500000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 57200000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 132740000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 132740000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Long Term Provisions: 134080000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Minority Interests: 0.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Net Income: 397590000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 397590000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 397590000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 397590000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 397590000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 397590000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Net Interest Income: -5990000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -5990000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Net PPE: 854750000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 6979160000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Assets: 126170000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Non Current Prepaid Assets: 203220000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 594150000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Normalized Income: 397590000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Operating Income: 975110000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Operating Revenue: 2826950000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 15519739.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 393050000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 222150000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Other Equity Interest: 6881300000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 57340000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 92760000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: -524560000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Other Properties: 854750000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 845230000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Otherunder Preferred Stock Dividend: 0.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Payables: 932400000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Pretax Income: 513800000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 1777480000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 74360000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Share Issued: 15519739.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Special Income Charges: 0.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 7036500000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 6979160000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Tax Provision: 116210000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.23
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Total Assets: 9159350000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 7036500000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Total Debt: 201640000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 7036500000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Total Expenses: 1851840000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 2122850000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 2612770000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 321530000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 103950000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items: 0.00
EXPLEOSOL.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: 0.00
EXPLEOSOL.NS balance_sheet (quarterly, 2025-09-30) — Working Capital: 4745260000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 680570000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 2793460000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 15517532.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 14.26
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 1725230000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 73010000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 73010000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 15517532.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 14.26
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 221280000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — EBIT: 323680000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — EBITDA: 396690000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 1068230000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 4220000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 4220000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Minority Interests: 0.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Net Income: 221280000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 221280000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 221280000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 221280000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 221280000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 221280000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -4220000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -4220000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 564570000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 337565251.36
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Operating Income: 387660000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 2793460000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 103900000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 607560000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Other Special Charges: 167880000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 319460000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 1725230000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 73010000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: -167880000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -51594748.64
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 98180000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.31
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 2405800000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: -167880000.00
EXPLEOSOL.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -167880000.00
EXPLEOSOL.NS income_statement (annual, 2026-03-31) — +Operating Expense: 2616850000.00
EXPLEOSOL.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 614410000.00
EXPLEOSOL.NS income_statement (annual, 2026-03-31) — +Total Revenue: 11079630000.00
EXPLEOSOL.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 2862750000.00
EXPLEOSOL.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 571410000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 571410000.00
EXPLEOSOL.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 2295590000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 2295590000.00
EXPLEOSOL.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 42000000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 42000000.00
EXPLEOSOL.NS income_statement (annual, 2026-03-31) — Basic Average Shares: 15519089.00
EXPLEOSOL.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 15519553.00
EXPLEOSOL.NS income_statement (annual, 2026-03-31) — Basic EPS: 79.89
EXPLEOSOL.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 26.85
EXPLEOSOL.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 2174860000.00
EXPLEOSOL.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -29640000.00
EXPLEOSOL.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 78520000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 78520000.00
EXPLEOSOL.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 155200000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 155200000.00
EXPLEOSOL.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 3542520000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 3542520000.00
EXPLEOSOL.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 4509290000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 4509290000.00
EXPLEOSOL.NS cash_flow (annual, 2026-03-31) — Change In Other Current Assets: 45630000.00
EXPLEOSOL.NS cash_flow (annual, 2026-03-31) — Change In Other Current Liabilities: -315210000.00
EXPLEOSOL.NS cash_flow (annual, 2026-03-31) — Change In Payable: -26910000.00
EXPLEOSOL.NS cash_flow (annual, 2026-03-31) — Change In Receivables: 18450000.00
EXPLEOSOL.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: -234980000.00
EXPLEOSOL.NS cash_flow (annual, 2026-03-31) — Changes In Cash: 1418780000.00
EXPLEOSOL.NS balance_sheet (annual, 2026-03-31) — Common Stock: 155200000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 155200000.00
EXPLEOSOL.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 7763120000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 7763120000.00
EXPLEOSOL.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 7046380000.00
EXPLEOSOL.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 1880160000.00
EXPLEOSOL.NS balance_sheet (annual, 2026-03-31) — Current Assets: 7111810000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 7111810000.00
EXPLEOSOL.NS balance_sheet (annual, 2026-03-31) — Current Capital Lease Obligation: 27940000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 27940000.00
EXPLEOSOL.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 27940000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 27940000.00
EXPLEOSOL.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 1280830000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 1280830000.00
EXPLEOSOL.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 147730000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 147730000.00
EXPLEOSOL.NS cash_flow (annual, 2026-03-31) — Depreciation: 283260000.00
EXPLEOSOL.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 283260000.00
EXPLEOSOL.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 283260000.00
EXPLEOSOL.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 59170000.00
EXPLEOSOL.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 283260000.00
EXPLEOSOL.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 59170000.00
EXPLEOSOL.NS income_statement (annual, 2026-03-31) — Diluted Average Shares: 15519089.00
EXPLEOSOL.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 15519553.00
EXPLEOSOL.NS income_statement (annual, 2026-03-31) — Diluted EPS: 79.89
EXPLEOSOL.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 26.85
EXPLEOSOL.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 1239820000.00
EXPLEOSOL.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 416700000.00
EXPLEOSOL.NS income_statement (annual, 2026-03-31) — EBIT: 1648000000.00
EXPLEOSOL.NS income_statement (quarterly, 2026-03-31) — EBIT: 514560000.00
EXPLEOSOL.NS income_statement (annual, 2026-03-31) — EBITDA: 1931260000.00
EXPLEOSOL.NS income_statement (quarterly, 2026-03-31) — EBITDA: 573730000.00
EXPLEOSOL.NS cash_flow (annual, 2026-03-31) — Effect Of Exchange Rate Changes: -51120000.00
EXPLEOSOL.NS cash_flow (annual, 2026-03-31) — End Cash Position: 3542520000.00
EXPLEOSOL.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: -94550000.00
EXPLEOSOL.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: 1165020000.00
EXPLEOSOL.NS cash_flow (annual, 2026-03-31) — Gain Loss On Investment Securities: -37550000.00
EXPLEOSOL.NS cash_flow (annual, 2026-03-31) — Gain Loss On Sale Of PPE: -120000.00
EXPLEOSOL.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 4920000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 4920000.00
EXPLEOSOL.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 721800000.00
EXPLEOSOL.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 721800000.00
EXPLEOSOL.NS income_statement (annual, 2026-03-31) — Gross Profit: 4033250000.00
EXPLEOSOL.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 982590000.00
EXPLEOSOL.NS income_statement (annual, 2026-03-31) — Interest Expense: 22350000.00
EXPLEOSOL.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 5730000.00
EXPLEOSOL.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 22350000.00
EXPLEOSOL.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 5730000.00
EXPLEOSOL.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -20040000.00